Scarica l'app Stockscreener
49.81
15.84%
6.81
Dopo l'orario di chiusura:
52.50
2.69
+5.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$43.00
Aprire:
$43.5
Volume 24 ore:
21.57M
Relative Volume:
1.91
Capitalizzazione di mercato:
$19.46B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-5.7056
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
+22.75%
1M Prestazione:
+47.37%
6M Prestazione:
+60.83%
1 anno Prestazione:
+38.79%
Intervallo 1D:
$43.34
$50.00
Intervallo di 1 settimana:
$39.25
$50.00
Portata 52W:
$22.28
$50.00
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
49.81 | 16.80B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.14 | 112.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.33 | 77.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.37 | 50.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
365.46 | 46.97B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.64 | 36.99B | 4.98B | 69.59M | 525.67M | 0.5197 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna and Merck pop on cancer vaccine, Lucid-Rockwell partnership - Yahoo! Finance Canada
Moderna Stock Rallies as Oncology Results Improve the Platform’s Value Case - Investing.com
Moderna Stock Skyrockets To 52-Week High: What's Behind The Surge? - Benzinga
Moderna (NASDAQ:MRNA) Sets New 1-Year HighWhat's Next? - MarketBeat
Moderna (MRNA) Shares Skyrocket, What You Need To Know - Finviz
Promising Biotech Stocks To ConsiderJanuary 21st - MarketBeat
Why Is Moderna (MRNA) Stock Up Today: Merck Partnered Vaccine Cuts Recurrence Risk - Tokenist
Moderna stock hits 52-week high at $45.44 By Investing.com - Investing.com Australia
Moderna stock hits 52-week high at $45.44 - Investing.com
The Truth About Moderna Inc: Is MRNA Still a Pandemic One-Hit Wonder or a Silent Beast? - AD HOC NEWS
Sumitomo Mitsui Trust Group Inc. Reduces Position in Moderna, Inc. $MRNA - MarketBeat
Moderna Cancer Data Sparks Questions On Oncology Pivot And Stock Valuation - simplywall.st
BofA Raises Moderna Price Target to $27, Maintains Underperform Rating - Intellectia AI
Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious - Stocktwits
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Merck/Moderna Intismeran Data Show Continued Efficacy In Melanoma - Citeline News & Insights
Moderna–Merck Cancer Vaccine Shows Durable Benefit At 5 Years In High-Risk Melanoma - Benzinga
Moderna, Merck's skin cancer vaccine shows sustained benefit in five-year follow-up - Reuters
Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High? - MarketBeat
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play - TechStock²
Moderna's Options: A Look at What the Big Money is Thinking - Benzinga
Moderna, Merck’s skin cancer vaccine shows sustained benefit in long-term follow-up - whtc.com
Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update - Stocktwits
Moderna rises as cancer vaccine shows long-term benefit in melanoma study - TradingView — Track All Markets
New personalized skin cancer treatment shows success in preventing return of melanoma - The Independent
Moderna and Merck confirm the lasting effectiveness of their skin cancer vaccine - marketscreener.com
Moderna and Merck report 5-year data for intismeran autogene - The Pharma Letter
Intismeran Autogene + KEYTRUDA Improves 5-Year Recurrence-Free Survival In Melanoma, Moderna & Merck - Nasdaq
Moderna's (MRNA) Cancer Therapy Shows Promising Results in Late-Stage Trial - GuruFocus
Moderna, Merck Report Positive Results From Cancer-Vaccine Study - The Wall Street Journal
Moderna cancer therapy with Merck’s Keytruda cut mortality by 49% in mid-stage trial - Seeking Alpha
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Compl - Investing News Network
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melano - ACCESS Newswire
Moderna, Merck Show Long-Term Survival for mRNA-Keytruda Combo - BioSpace
Moderna and Merck report sustained melanoma treatment benefits at 5 years - StreetInsider
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy UpdatesFDL Reporter | The Reporter - fdlreporter.com
Moderna Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily
Moderna (MRNA) Valuation Check After Raised 2025 Outlook And Cost Cuts At JPMorgan Conference - Yahoo Finance
Moderna Shares Surge Amid Positive Earnings and Regulatory News - StocksToTrade
Moderna’s Market Gains as Revenue Projections Boost Investor Confidence - timothysykes.com
Moderna stock price pops 6% into the weekend — here’s what traders are watching next for MRNA - TechStock²
OVERSEA CHINESE BANKING Corp Ltd Sells 37,172 Shares of Moderna, Inc. $MRNA - MarketBeat
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - The Daily News Journal
Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of "Reduce" by Analysts - MarketBeat
Moderna (NASDAQ:MRNA) Upgraded at Wall Street Zen - MarketBeat
Moderna Stock vs Competition: Who Wins? - Trefis
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - registerguard.com
Weekly Market Update: Stocks Remain Flat as Consumer Defensives Rise and Financial Services Fall - morningstar.com
I Hope Moderna (MRNA) Posts Growth, Says Jim Cramer - Finviz
Moderna (NASDAQ:MRNA) Shares Gap UpStill a Buy? - MarketBeat
Moderna's Fourth Quarter 2025 Financial Results: Anticipated Highlights - Bitget
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moderna Inc Azioni (MRNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| AFEYAN NOUBAR | Director |
Dec 11 '25 |
Sale |
29.48 |
23,853 |
703,306 |
3,924 |
| Bancel Stephane | Chief Executive Officer |
Dec 11 '25 |
Option Exercise |
10.90 |
688,073 |
7,499,996 |
6,181,970 |
5.17%
4.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):